Background: Fibroblast growth factor (FGF)-2 has the potential to enhance tendon-to-bone healing after rotator cuff (RC) injury.
A rotator cuff (RC) injury is one of the most common causes of shoulder pain and dysfunction, often requiring surgical repair. Despite great improvement in surgical techniques for repairing RC tears, a recent meta-analysis of 14 studies reported on an imaging assessment of the structural integrity of RC repair, and it demonstrated a high rate of failed repair (21.7%; 187/861 patients) at the latest follow-up. 14 Therefore, developing new strategies to enhance tendonto-bone healing is imperative.
Various growth factors are endogenously expressed during tendon-to-bone healing, suggesting that they play critical roles in the repair process, 27 and there is interest regarding their use as therapeutic agents for enhancing RC repairs. Of those, fibroblast growth factor-2 (FGF-2) is a potent mitogen for a wide variety of cells, including mesenchymal stem cells (MSCs) and progenitor cells. 11, 19, 25 We previously demonstrated that the local administration of FGF-2 accelerates the initial tendon-to-bone healing as indicated by biomechanical tests and histological analyses after supraspinatus tendon repair in rats. 9 However, the biological mechanism of the reparative enhancement by FGF-2 during RC healing is unclear.
Recently, several genes have been identified as specific tendon markers. Scleraxis (Scx) is a basic helix-loop-helix transcription factor that is expressed in both tenogenic progenitors and tenocytes. 13, 15 Tenomodulin (Tnmd) is a type II transmembrane protein that is specifically expressed in dense connective tissues such as tendons and ligaments. 17, 18 Tnmd is detected in mature tenocytes and is positively regulated by Scx. 3, 18 Identification of these marker genes enables us to study in detail the cellular and molecular events that occur during the establishment of the osteotendinous junction. Recently, we reported that a subset of Scx-positive progenitors with an expression history of SRY-box containing gene 9 (Sox9) contributes to the formation of enthesis during development. 20 The purpose of this study was to investigate the effects of FGF-2 administration on cell proliferation and the expression of enthesis-related marker genes (ie, Scx, Sox9, and Tnmd) during RC tendon-to-bone healing in rats. The effects on biomechanical strength and histological appearance during healing were also investigated. We hypothesized that FGF-2 stimulates the tenogenic differentiation of progenitors and improves the biomechanical strength and histological appearance of repaired RCs in rats.
METHODS

Study Design
This study was approved by our institution's Animal Studies Committee and the Institutional Animal Care and Use Committee. We used a rat RC healing model, in which the supraspinatus tendon insertion site was transected and surgically repaired immediately, to investigate the effects of FGF-2 on tendon-to-bone healing. In this model, a normal tendon-to-bone insertion site is not regenerated even after 16 weeks postoperatively. 23 We included 156 adult male Sprague-Dawley rats (19-21 weeks old; mean 6 SD weight, 475 6 37 g) that underwent unilateral surgery for supraspinatus tendon repair immediately after transection, and they were randomly allocated to the control group or FGF-2-treated group (n = 78 per group). In the control group, gelatin hydrogel sheets (MedGEL Co) with phosphate-buffered saline (PBS) were applied between the supraspinatus tendon and bone. In the FGF-2-treated group, gelatin hydrogel sheets containing 5 mg of recombinant human FGF-2 (Kaken Pharmaceutical Corp) were applied. All rats were sacrificed at 2, 4, 6, 8, or 12 weeks postoperatively. At each time point, 6 specimens per group were used for histological evaluation (ie, histology, immunohistochemistry, or in situ hybridization), and 6 per group were analyzed with real-time reverse transcription polymerase chain reaction (RT-PCR). At 6 and 12 weeks, 9 specimens per group were used for biomechanical testing.
Local Administration of FGF-2
We used a biodegradable gelatin hydrogel sheet 21 (MedGel PI5, MedGEL Co) as a carrier for the FGF-2. In our pilot study, 3 doses of FGF-2 (0.5, 5, and 50 mg per site) in gelatin hydrogel sheets were compared between the carrieronly and suture-only groups by use of the same method in the present study (n = 6 per group underwent histological and biomechanical testing). At 12 weeks postoperatively, a significant improvement in the ultimate load to failure was achieved in all FGF-2-treated groups (mean 6 SD: 0.5 mg, 29.1 6 10.1 N; 5 mg, 31.7 6 8.5 N; and 50 mg, 25.9 6 8.6 N) compared with the carrier-only group (15.8 6 4.5 N) and the suture-only group (12.4 6 2.4 N). The histological scores in the FGF-2-treated groups (0.5 mg, 9.7 6 1.0; 5 mg, 10.7 6 0.5; and 50 mg, 10.3 6 0.5) were higher than those in the suture-only group (7.5 6 0.5) and the carrier-only group (7.8 6 0.8). Although there were no significant differences among the 3 groups that were treated with FGF-2, we used the 5-mg dose of FGF-2, because the 5-mg FGF-2-treated group showed the highest histological score and the ultimate load to failure.
Before administration, freeze-dried gelatin hydrogel sheets (1 mg) for each shoulder were soaked with 10 mL of PBS or FGF-2 (500 mg/mL), and the sheets were incubated for 60 minutes at room temperature.
Surgical Procedure
The rats underwent left shoulder surgery, as previously described. 6, 23 Briefly, after the administration of general anesthesia with an intraperitoneal injection of pentobarbital (25-30 mg/kg), longitudinal anterolateral skin and deltoid muscle incisions were made, and the supraspinatus tendon was exposed. The supraspinatus tendon was detached sharply at its insertion (3 mm in the anteriorposterior dimension), and the fibrocartilaginous stump on the greater tuberosity was completely removed by use of a high-speed bur until bleeding was observed. A 0.8-mm drill hole was created transversely in an anterior-posterior orientation through the proximal part of the humerus. We sutured the torn supraspinatus tendon to its anatomic position using a double-armed 5-0 prolene suture (Ethicon) using a modified Mason-Allen method. A gelatin hydrogel sheet soaked with PBS or FGF-2 was fixed to the torn end of the tendon by use of a 5-0 prolene suture, which is used for repair, and the sheet was secured between the tendon and bone. The incision was closed in layers with 4-0 nylon sutures. All rats were permitted cage activities without immobilization postoperatively.
Biomechanical Testing
As previously described, 9, 26 9 animals per group were tested at 6 and 12 weeks postoperatively, and 9 intact shoulders were used as a normal control. All specimens were frozen at -80°C until testing. After thawing, the supraspinatus tendon repair to the humerus was dissected from the surrounding tissues with a custom-designed double scalpel blade to a 2-mm width to standardize the tendon tested, and the supraspinatus muscle belly and any scar tissue were removed. Each specimen was preloaded to 0.1 N and loaded to failure with a conventional tensile tester (STA1225; Orientec) at a rate of 10 mm/min, and the ultimate load to failure and the failure site were recorded. The linear region of the load-displacement curve was used to calculate the stiffness. The cross-sectional area of the repaired insertion site, including its width and thickness, was measured using a digital microcaliper. 7 The ultimate load to failure was divided by the cross-sectional area of the repair site to determine the ultimate stress to failure.
Histological Evaluation
The tissues were fixed overnight in 4% paraformaldehyde at an abduction angle of 30°and were decalcified in Morse solution (10% sodium citrate and 22.5% formic acid). After decalcification, the tissues were dehydrated and embedded in paraffin. The sections were viewed under an Olympus BX-51 microscope (Olympus Optical), and digital images were taken with a DP70 camera (Olympus Optical). To evaluate healing at the tendon-to-bone site semiquantitatively, we used a computerized image analysis (Image J; National Institutes of Health) and a modified scoring system (Table 1 ) based on previously reported histological evaluations. 24, 26, 28 We scored the healing insertion site according to 3 histological parameters (ie, cellularity, vascularity, and collagen fiber orientation). Three sequential sections were obtained from each animal for each staining, and the results were averaged.
To analyze cellularity, all cell nuclei in a randomly selected region of interest (200 3 200 mm) were counted to calculate the number per square millimeter at the insertion site (100-400 mm proximal to the bone trough) on hematoxylin and eosin (HE)-stained slides under 100-fold magnification.
To analyze vascularity, all blood vessels were counted to calculate the mean vessel number from 3 sequential sections at the insertion site (100-400 mm proximal to the bone trough) on HE-stained slides under 100-fold magnification.
The collagen fiber orientation was assessed by Picrosirius Red-stained sections by use of a polarizing microscope. 7, 26 On 8-bit digitized images, intense white areas of brightly diffracted light on a gray scale (black, 0; white, 255) were observed. Higher gray scales indicated more organized collagen fibers. We randomly selected 10 square areas (100 3 100 mm) at the insertion site (100-400 mm proximal to the bone trough) under 12.5-fold magnification, and gray scales were measured by use of Image J. The values from the 10 areas were averaged to obtain a value of average gray scales per specimen. To reduce sampling errors, we took photomicrographs of 3 sequential sections from each specimen under the same illumination conditions. Cellularity and collagen fiber orientation were scored using the percentage of the value measured in 6 right shoulders (intact side). A perfect score is 12 points (Table  1) . Analysis was performed by 2 colleagues who were blinded to the groups for each specimen and the time points throughout the histological examinations.
Immunohistochemical Analysis
Semiserial sections (4 mm) were prepared for immunostaining. To assess the cell proliferation, the expression Number of cells per region of interest from each section; percentages represent relative values compared with the values from normal tendon-to-bone sections (n = 6), which were set at 100%.
b
Number of blood vessels (bv) per low power field (PF) (100-fold magnification) from each section. Gray scale per region of interest from each section as measured using Image J; percentages represent relative values compared with the values from normal tendon-to-bone sections (n = 6), which were set at 100%.
of Sox9, and the existence of MSCs, we performed immunostaining for proliferating cell nuclear antigen (PCNA) and Sox9 at all time points, for MSC-related surface antigens (CD105, CD90, and CD73) at 2 and 4 weeks postoperatively, and for hematopoietic cell antigen (CD45 and CD34) at 2 and 4 weeks postoperatively. 
Estimation of Cell Proliferation and the Expression of Sox9 at the Healing Site
To estimate cell proliferation at the healing site, we modified the previously described method for PCNA-positive cell counting. 
RNA Isolation and Real-Time RT-PCR
At all time points, the left (operative side) and right (intact side) tendon-to-bone tissues were dissected and flash frozen in liquid nitrogen and crushed by use of a Multi-beads Shocker (Yasui Kikai). After homogenization, total RNA was extracted and purified per the manufacturer's instructions using the TRIzol Plus RNA Purification Kit (Invitrogen). The total RNA (1 mg) was reverse transcribed to complementary DNA (cDNA) using the Thermoscript RT kit (Invitrogen). Real-time PCR was performed using an ABI7500 system (Applied Biosystems) with TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assays for the following genes: Scx (Assay ID: Rn01504576_m1), Tnmd (Rn00574164_m1), Sox9 (Rn01751069_mH), and 18S ribosomal RNA (Rn03928990_g1). Each sample was analyzed in duplicate. The relative expression levels for the target genes were analyzed using the comparative Ct method. The delta-Ct values were calculated by the difference between the Ct values of the target genes and 18S ribosomal RNA. The results are represented as the relative gene expression compared with the intact tendon. 16 
In Situ Hybridization
In situ hybridization was performed to detect the expression of Scx and Tnmd messenger RNA (mRNA) as previously described. 1 Briefly, 5-mm sections were deparaffinized, rehydrated, incubated with proteinase K (20 mg/mL; Gibco BRL), postfixed in 4% paraformaldehyde, acetylated with 0.1 M triethanolamine containing 0.25% acetic anhydride for 10 minutes, dehydrated, and air-dried.
Sense and antisense RNA probes labeled with digoxigenin (DIG) for Scx or Tnmd were synthesized by in vitro transcription with a DIG RNA labeling kit (Roche) using the following cDNA clones: Rat Scx cDNA containing a 0.726-kb fragment was subcloned into pBSII SK1 (Stratagene), and rat Tnmd cDNA containing a 0.607-kb fragment was subcloned into pCRII-TOPO (Invitrogen), as a template after linearization. Hybridization was performed at 50°C for 16 hours. After hybridization, the sections were washed in 23 standard saline citrate (SSC) containing 50% formamide, were treated with RNase A (20 mg/mL), and were washed again in 23 SSC. Immunological probe detection was performed with an anti-DIG-AP Fab fragment (Roche) and BM Purple (Roche). The specificity of these antisense probes was confirmed on mouse embryo (E16.5) sections as positive controls. Sense probes for Scx and Tnmd were used on sections as negative controls.
Evaluation of Association Between the Locations of Reparative Tissue Accompanying Collagen Fibers With an Aligned Orientation and Scx or Tnmd mRNA
To investigate the correlation between the location of healing tissues with aligned collagen fiber orientation and the localization of Scx or Tnmd mRNA, images from Picrosirius Red staining and in situ hybridization in sections in the treatment and control groups at 8 weeks postoperatively (n = 12) were evaluated, and 9 areas (tendon, suture, and insertion areas of the articular side, middle, and bursal side) were determined. Collagen fiber orientation for each area was evaluated by applying the gray scale as described above. Expression levels of Scx or Tnmd mRNA (density of hybridization signals) in each area were graded by use of previously reported 23 standards to define high (4), moderate (3), low (2), and undetectable (1) levels, and the highest grade for each area from each specimen was recorded.
Statistical Analysis
Before the study initiation, a power analysis was performed with the G*Power 3.1 program, 5 which we used in our pilot study described above, which entailed a similar rat model. A minimum of 9 specimens per group for each time point were required for biomechanical testing (Cohen d, 1.45), and a minimum of 6 specimens per group for each time point were required for histological evaluation (Cohen d, 2.04), with an a value of .05 and a power of 0.80 based on the effect size. The sample size for realtime RT-PCR was determined according to the power analysis for histological evaluation. Our primary analysis compared measurements between the groups at each time point, and the secondary analysis compared measurements within the groups over time. We used nonparametric statistical methods for all the analyses, because the data were nonnormally distributed. Statistical significance between the groups at each time point was estimated by use of the Mann-Whitney U test. Differences in the measurements within groups over time were analyzed with the Kruskal-Wallis test, followed by the post hoc Scheffé test for multiple comparisons. Correlations between the collagen fiber orientation and the expression levels of Scx or Tnmd mRNA were assessed with Spearman correlation analysis. Values of P \ .05 were considered statistically significant.
RESULTS
Biomechanical Testing
Three of 9 specimens from the normal shoulders failed at the insertion site; the other 6 failed at the tendon midsubstance. All specimens from the operated groups failed at the site of surgical repair (Table 2) .
At 6 weeks postoperatively, the ultimate load to failure, stiffness, and ultimate stress to failure were significantly higher in the FGF-2-treated group than in the control group. No significant differences were observed between the groups in the cross-sectional area of the repair site.
At 12 weeks postoperatively, the ultimate load to failure and ultimate stress to failure were significantly higher in the FGF-2-treated group than in the control group. No significant differences were observed between the groups in the stiffness and cross-sectional area of the repair site.
Histological Analysis
Effects of FGF-2 on the Histological Appearance. At 2 weeks postoperatively, hypercellular and hypervascular granulations were noted in the insertion site (Figure 1 , A and G), and areas of brightly diffracted polarized light were rarely observed at the insertion site in any of the groups (Figure 1, D and J) .
From 6 to 12 weeks, although granulations decreased compared with the previous time point, the tendon-tobone area remained hypervascular and filled with disorganized collagen fibers in the control group (Figure 1 , B, C, E, and F). Conversely, in the FGF-2-treated group, these granulations were decreased, and the area of brightly diffracted polarized light at the insertion site was larger than that in the control group (Figure 1, H, I , K, and L). The histological differences between the treatment group and control group were observed at 4 weeks.
At the bone surface, normal fibrocartilaginous enthesis was not regenerated in any specimen from any group at any time point.
In both groups, cellularity and vascularity decreased, but the collagen fiber orientation and total histological scores increased with time ( Table 3 ). The mean number of blood vessels at the insertion site was significantly smaller in the FGF-2-treated group than in the control group at 8 and 12 weeks postoperatively. Collagen fiber orientation and the total score were significantly higher in the FGF-2-treated group than in the control group at 4 weeks.
Effects of FGF-2 on Cell Proliferation. At 2 and 4 weeks postoperatively, greater numbers of PCNA-positive cells were observed in the granulation tissue between the tendon and bone in the FGF-2-treated group than in the control group (Figure 2, A and C) . At 6 weeks, PCNA-positive cells obviously decreased and were mainly present at the bone surface in both groups (Figure 2, B and D) . The percentage of PCNA-positive cells was significantly larger in the FGF-2-treated group than in the control group at 2 weeks (45.4% 6 9.3% vs 30.8% 6 5.7%; P = .016) and 4 weeks (41.9% 6 8.0% vs 29.0% 6 7.4%; P = .025). There were no differences between the groups at 6 weeks (control, 21.2% 6 4.6%; FGF-2-treated, 23.8% 6 5.3%; P = .423), 8 weeks (control, 19.7% 6 2.7%; FGF-2-treated, 22.3% 6 5.7%; P = .263), and 12 weeks (control, 19.0% 6 3.8%; FGF-2-treated, 19.6% 6 5.3%; P = .749) ( Figure 2E) .
Effect of FGF-2 on the Expression of Scx and Tnmd. Real-time RT-PCR analysis showed that a significantly higher expression of Scx was detected in the FGF-2-treated group than in the control group at 4, 6, and 8 weeks (P = .010, .010, and .004, respectively). There were no differences between the control and FGF-2 groups at 2 and 12 Biomechanical values expressed as mean 6 SD. n = 9 for each treatment at both time points. FGF-2, fibroblast growth factor-2. Significantly different between time points within group (P \ .05). * Significantly different between groups at the same time point (P \ .01).
weeks (P = .631, and .150, respectively) ( Figure 3A) . Tnmd expression was significantly higher in the FGF-2-treated group than in the control group at 4, 6, 8, and 12 weeks (P = .004, .010, .004, and .016, respectively). There were no differences between the groups at 2 weeks (P = .631) ( Figure 3B ). Scx expression was transiently upregulated from 4 to 8 weeks; meanwhile Tnmd expression was persistently upregulated by FGF-2 treatment even after 12 weeks postoperatively (Figure 3) .
We then performed in situ hybridization to analyze the localization of Scx and Tnmd mRNA. In both groups, hybridization signals for Scx were detected in the spindle-shaped cells at the tendon midsubstance at all time points (Figure 4 , A, D, M, and P), and a few hybridization signals for Scx were detected in the round and spindleshaped cells within the granulation tissue around the suture at 4, 6, and 8 weeks (data not shown). In the control, hybridization signals for Scx were rarely detected within the fibrovascular tissue at the bone surface at any time points (Figure 4 , G and J). However, in the FGF-2-treated group, Scx was expressed in the spindle-shaped cells at the bone surface at 4 weeks ( Figure 4V ).
Tnmd signals were also detected in the spindle-shaped cells at the tendon midsubstance in both groups at all time points, and hybridization signals increased with time ( Figure 4 , B, E, N, and Q). In the FGF-2-treated group, the distribution of these signals expanded into reparative tissues near the suturing site compared with the control. However, Tnmd was rarely detected at the bone surface in either group at any time point (Figure 4 , H, K, T, and W).
Correlation Between the Locations of Healing Tissue With Aligned Collagen Fiber Orientation and Scx or Tnmd mRNA
We assessed 108 areas in both groups at 8 weeks postoperatively ( Figure 5) . A weak, positive correlation between the location of aligned collagen fiber orientation and expression levels of Scx mRNA in each area was observed (Spearman rank correlation [r] = 0.27, P \ .001) ( Figure 5D ). Meanwhile, a strong positive correlation between the location of aligned collagen fiber orientation and the expression levels of Tnmd mRNA in each area was observed (r = 0.88, P \ .001) ( Figure 5E ).
Effect of FGF-2 on Sox9 Expression
Real-time RT-PCR analysis showed that Sox9 expression was significantly higher in the FGF-2-treated group than in the control group at 4 weeks (P = .004). However, at 2, 6, 8, and 12 weeks, there were no statistically significant Histological values expressed as mean 6 SD. n = 6 for each treatment at all time points. FGF-2, fibroblast growth factor-2. differences between the groups (P = .337, .749, .200, and .337, respectively) ( Figure 6 ). In immunostaining for Sox9 (Figure 7 ), Sox9-positive cells were mainly observed at the tendon-to-bone insertion site, but a few Sox9-positive spindle-shaped cells were also detected at the tendon midsubstance at 4 weeks in both groups. The percentage of Sox9-positive cells was significantly higher in the FGF-2-treated group than in the control group at 4 weeks (23.7% 6 4.9% vs 14.0% 6 3.6%; P = .010). There were no differences between the groups at 2 weeks (control, 10.1% 6 4.8%; FGF-2-treated, 13.4% 6 6.6%; P = .337), 6 weeks (control, 19.7% 6 2.7%; FGF-2-treated, 22.3% 6 5.7%; P = .263), 8 weeks (control, 10.3% 6 1.1%; FGF-2-treated, 11.2% 6 1.5%; P = .423), and 12 weeks (control, 10.1% 6 2.6%; FGF-2-treated, 11.3% 6 3.4%; P = .749) ( Figure 7I ).
Effect of FGF-2 on MCS Marker-Positive Cells in the Early Phase of Healing
To analyze MSCs, serial sections were immunostained for MSC-related surface antigens (CD105, CD90, and CD73) and hematopoietic cell antigen (CD45 and CD34) at 2 and 4 weeks postoperatively. CD45-and CD34-positive cells were rarely detectable at the insertion site in either group. In the FGF-2-treated group, cells positive for CD105, CD90, and CD73 were detected more within the reparative tissue at the insertion site than in the control group (Figure 8 ).
DISCUSSION
Our findings support our hypothesis that FGF-2 stimulates the tenogenic differentiation of progenitors to improve the biomechanical strength and histological appearance of repaired RCs in rats. Previous studies 6, 23 have described the healing response as observed using histological evaluation in a rat RC acute injury and immediate repair model, and the healing response occurred almost exclusively within the tendon-to-bone insertion site that was filled with hypercellular and hypervascular granulation tissues by postoperative day 10. As healing progresses, cellularity and vascularity decrease, and then the improvement of collagen fiber orientation and fiber integration into the bone is observed to some extent. However, a histologically normal tissue is not regenerated. Instead, the disorganized fibrovascular scar interposes at the insertion site without supplementation of growth/ differentiation factors. 23 Without FGF-2 administration, in this study, the fibrovascular scar interposed between the tendon and bone even 12 weeks after RC repair surgery. In contrast, the administration of FGF-2 clearly decreased the occurrence of fibrovascular scarring at the insertion site and increased the aligned orientation of collagen fibers at 4 weeks, as indicated by significantly higher histological scores (Figure 1 and Table 3 ). Moreover, even though normal biomechanical strength was not achieved at 12 weeks postoperatively (ultimate load to failure, 56.7% of normal controls; stiffness, 33.3% of normal controls; ultimate load to stress, 35.1% of normal controls), FGF-2 administration significantly increased the biomechanical strength by 6 weeks postoperatively ( Table 2 ).
In an ovine study model on tendon-to-bone healing, the disorganized fibrovascular scar at the insertion site was weaker than the axially aligned collagen fibers in the bone. 8 These results suggest that the improvement of mechanical strength by FGF-2 treatment is associated with decreases in the fibrovascular scarring and improvement in the collagen fiber orientation at the insertion site.
Accumulating evidence suggests that Scx-expressing tenogenic cells can participate in a regenerative repair of tendons to promote the formation of collagen fibers with an aligned orientation, which have better tensile strength. Gulotta et al 7 demonstrated that application of bone marrow-derived MSCs transduced with Scx resulted in an improvement in histological and biomechanical properties at 4 weeks postoperatively in a similar rat RC healing model. Tan et al 22 also reported that transplantation of Scx-transduced tendon-derived stem cells provided better tendon repair than mock-transduced cells in a rat patellar tendon injury model from histological and biomechanical viewpoints.
Our study showed that FGF-2 administration induced Scx expression in the cells of healing tissue 4 to 8 weeks postoperatively, indicating that more tenogenic progenitor cells were generated at the healing sites from the mid to late stages of healing (Figures 3 and 4) . During differentiation from tenogenic progenitors to mature tenocytes, the Scx expression declines, while Tnmd is continuously expressed. 10, 18 In murine tendon development, Scx expression increases from E10.5 to E12.5 and decreases at E13.5; meanwhile, the expression of Tnmd sharply increases from E13.5 and persists until the late stage in the forelimb tendon cells. 10 These temporal expression patterns of Scx and Tnmd were also demonstrated in mouse patellar healing. 16 In this study, Tnmd-positive tenocyte-like cells were persistently observed until the later stage of healing from 4 to 12 weeks postoperatively. Interestingly, Tnmd-positive tenocyte-like cells were only observed in the area with highly oriented collagen fibers. In particular, these cells were distributed into the reparative tissues near the suturing site in the FGF-2-treated group 4 to 12 weeks postoperatively, which was consistent with highly oriented collagen fiber areas as shown by the histological evaluation in this study ( Figure 5E ). These spatial patterns of Tnmd expression are similar to those seen in the late stage of tendon development, 18 suggesting that Tnmd is a useful marker for evaluating the differentiation of mature tenocyte-like cells in tendon healing. Despite the enhanced differentiation of Tnmd-positive tenocyte-like cells, it is unlikely that FGF-2 directly stimulated tenogenic differentiation of cells in this later phase of RC healing, since FGF-2 is known to be released from gelatin hydrogel sheets within 2 weeks. 21 Thus, the FGF-2-stimulated tenogenic repair responses in this study must be primarily mediated by the growth stimulation of undifferentiated mesenchymal cells, as indicated by a higher incidence of PCNA-positive cells at the repair sites during the early phase (Figure 2) . In a mouse patellar tendon healing model, 4 undifferentiated mesenchymal progenitors migrate from a paratenon to the healing site by 1 week after injury. Subsequently, Scx-expressing cells appear at 2 weeks or more, suggesting that the initial growth of undifferentiated mesenchymal progenitors has a critical role for the subsequent tenogenic differentiation of cells during the later phase of healing. In agreement with the previous in vitro studies 11, 19, 25 which have shown that FGF-2 potently stimulates the self-renewal of MSCs and/or progenitor cells without a loss of potentials for the subsequent cell differentiation, we demonstrated in the present study that the healing process started with a better accumulation of cells expressing MSC-related markers within 2 weeks in the FGF-2-treated group (Figure 8 ).
There are several limitations to the current study. First, our acutely created tear and immediate repair model does not reflect chronic degenerative RC tears, and our findings in this rat model may not directly translate to humans, because the healing processes in healthy animals may not mirror the situations encountered in clinical practice. However, based on anatomic similarities between humans, this model has been widely used to investigate the mechanism of healing 6, 23, 27 and the method of healing enhancement. 7, 9, 24 Second, this study did not directly identify the function of tenogenic marker genes during the RC healing process. Further studies using a knockout model on Scx or Tnmd are required to determine the roles of these genes during the RC healing process. Third, our findings demonstrated that the biomechanical and histological values of the control group did not reach those of the FGF-2-treated group by 12 weeks. A longer time period may be necessary to understand whether the effect observed in the FGF-2-treated group will persist throughout the healing response. Fourth, the sample size, which was based on the large effect size, was relatively small, and it may be underpowered to detect significant differences. Likewise, our histological evaluation may be underpowered, because it did not include all sections from the specimens. However, there was little or no discrepancy among our findings observed in various evaluation methods during RC healing. Fifth, direct clinical implications for treatment may be difficult to determine from this small animal model. Currently, little is known about the biological mechanisms underlying the RC healing response. 6 Therefore, basic research on these mechanisms may provide clues to determine the safety, effect, dose, and method of administration in larger models. Ultimately, human clinical trials are also needed to translate these findings to clinical use.
It is not known whether FGF-2 can selectively facilitate the growth of undifferentiated tenogenic cells of a certain mesenchymal lineage. However, the enhanced expression of Scx and Tnmd genes in the mid to late stages indicates that a certain microenvironment favorable for the growth response of tenogenic progenitor cells to FGF-2 may be provided in the present RC healing model. Interestingly, the transient upregulation of Sox9 detected in the FGF-2-treated group at 4 weeks postoperatively may indicate that a possible occurrence of Sox9 and Scx double-positive tenogenic progenitors contributes to enthesis formation during development. 20 Thus, further analysis of the cellular components and the microenvironment at the RC repair sites will help develop clinical strategies for inducing a specific regenerative healing response in RC injuries.
